4-(3-甲基磺酰氧基丙基)苯甲酸甲酯 | 141018-99-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3-甲基磺酰氧基丙基)苯甲酸甲酯
• 英文名称: methyl 4-<3-(methanesulfonyloxy)propyl>benzoate
• 英文别名: 4-(3-methanesulfonyloxy-propyl)-benzoic acid methyl ester；4-(3-methanesulfonyloxypropyl)benzoic acid methyl ester；Methyl 4-(3-(methanesulfonyloxy)-1-propyl)benzoate；methyl 4-{3-[(methylsulfonyl)oxy]propyl}benzoate；methyl 4-(3-methylsulfonyloxypropyl)benzoate；Benzoic acid, 4-[3-[(methylsulfonyl)oxy]propyl]-, methyl ester
• CAS: 141018-99-7
• 化学式: C₁₂H₁₆O₅S
• 分子量: 272.322
• InChiKey: OBSPKAAAZCRZRD-UHFFFAOYSA-N

物化性质

• 沸点：
  445.9±38.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(3-甲基磺酰氧基丙基)苯甲酸甲酯 在 sodium azide 、 TEA 、 水 、 三苯基膦 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 methyl 4-<3-<<6-chloro-2-(pivaloylamino)pyrimidin-4-yl>amino>propyl>benzoate
  参考文献：
  名称：

  Novel 5-desmethylene analogs of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid as potential anticancer agents

  摘要：

  The synthesis and biological activity of novel 5-desmethylene analogues of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), a potent antitumor agent presently undergoing clinical trials, are described. These compounds are representative of a new series of optically pure analogues of DDATHF.

  DOI：

  10.1021/jo00037a047
• 作为产物：
  描述：

  4-(3-羟基-1-丙炔)苯甲酸甲酯 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 乙醇 、 氯仿 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 5.5h， 生成 4-(3-甲基磺酰氧基丙基)苯甲酸甲酯
  参考文献：
  名称：

  Further acyclic analogs of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid

  摘要：

  DOI：

  10.1021/jo00047a033

文献信息

• NOVEL PYRAZINE AMIDE COMPOUNDS
  申请人：WIEDENMAYER Dieter

  公开号：US20150045326A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , R 4 , R 5 , R 6 and X − have the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R4、R5、R6和X-的含义如规范中所示，以及它们作为药物的用途，用于治疗呼吸道疾病或疾病和过敏性呼吸道疾病中选择的疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。
• [EN] NOVEL PYRAZINE AMIDE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS PYRAZINE-AMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015018754A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6 and X- have one of the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R5、R6和X-具有规范中指示的含义之一，其用作药物，用于治疗呼吸道疾病或疾病和过敏性疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。
• Pyrimidinyl-glutamic acid derivatives
  申请人：Eli Lilly and Company

  公开号：US05426110A1

  公开（公告）日：1995-06-20

  The present invention provides novel pyrimidinyl-glutamic acid derivatives and intermediates thereto. Further provided are methods for inhibiting dihydrofolate reductase in mammals and for treating susceptible neoplasms in mammals, particularly humans.

  本发明提供了新型嘧啶基谷氨酸衍生物及其中间体。进一步提供了一种在哺乳动物中抑制二氢叶酸还原酶的方法，以及用于治疗哺乳动物中易感的肿瘤，特别是人类的方法。
• PYRIDONE COMPOUND
  申请人：Kamikubo Takashi

  公开号：US20100179137A1

  公开（公告）日：2010-07-15

  [Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position is bonded with an aromatic ring group via lower alkyl, lower alkylene, ether, or thioether, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action and a blood flow increasing action in the hindlimb of a rat, it is useful as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease.

  【解决方法】本发明者对EP4受体激动剂进行了广泛的研究，并发现一种新型吡啶酮化合物，其特征在于吡啶酮环中的1位被取代为具有酸性基团（如羧基）的基团，而6位则通过较低的烷基、烷基烷基、醚或硫醚与芳香环基团结合，具有极好的EP4受体激动作用，从而完成了本发明。由于本发明的化合物在大鼠后肢具有出色的EP4受体激动作用和增加血流的作用，因此可用作制药用途，特别是治疗周围动脉闭塞性疾病的药物。
• Pyrazine amide compounds
  申请人：Wiedenmayer Dieter

  公开号：US09096548B2

  公开（公告）日：2015-08-04

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R4, R5, R6 and X− have the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6和X-的含义如规范中所示，以及它们作为药物的用途，用于治疗呼吸道疾病或不适和过敏性呼吸道疾病，包括至少一种该化合物或其药学上可接受的盐的制药组合物，以及含有该化合物或其药学上可接受的盐之一或多个的药物组合物。